Items (Tables)

6 Months Ended

Oct. 31, 2014

Tables/Schedules

Earnings per Share Computation Table

	Three Months Ended October 31,		Six Months Ended October 31,
	2014	2013	2014	2013
Net loss allocable to common shareholders for basic and diluted net loss per common share	$         (274,914)	$         (957,836)	$         (779,118)	$      (1,543,210)
Weighted average common shares outstanding - basic	173,882,803	173,882,803	173,882,803	173,882,803
Effect of dilutive securities:
Warrants	0	0	0	0
Weighted average common shares outstanding - diluted	173,882,803	173,882,803	173,882,803	173,882,803
Net loss per common share - basic	$              (0.002)	$              (0.006)	$              (0.004)	$              (0.009)
Net loss per common share - diluted	$              (0.002)	$              (0.006)	$              (0.004)	$              (0.009)

Property and equipment table

(Estimated Life)	October 31, 2014 (unaudited)	April 30, 2014
Office equipment (5-7 Years)	$                62,378	$          58,266
Auto and trucks (10 Years)	940,518	929,042
Manufacturing equipment (20 Years)	12,078,334	11,987,404
Buildings (20 Years)	10,350,244	10,303,529
Construction in process	1,805,774	1,284,199
Gross Property and Equipment	25,237,248	24,562,440
Less: accumulated depreciation	(10,650,970)	(9,624,082)
Property and equipment, net	$        14,586,278	$  14,938,358

Schedule of Intangible Assets and Goodwill

(Estimated Life)	October 31, 2014 (unaudited)	April 30, 2014
Only Sweet name rights and related technologies (5 Years)	$      587,183	$      587,183
Distribution agreement and related distribution channels (5 Years)	1,038,691	1,038,691
Intangible assets, gross	1,625,874	1,625,874
Less: accumulated amortization	(704,546)	(541,959)
Intangible assets, net	$      921,328	$   1,083,915

Land use right table

(Estimated Life)	October 31, 2014 (unaudited)	April 30, 2014
Land use right (41-65 Years)	$   2,593,358	$   2,581,947
Less: accumulated amortization	(359,905)	(329,672)
Land use right, net	$   2,233,453	$   2,252,275

Schedule of due to related parties

	Pharmaceutical Corporation	Qufu Shengwang Import and Export	Total
Balance due to related parties, April 30, 2014	$      248,873	$       106,308	$      355,181
Working capital advances from related parties	0	46,044	46,044
Repayments	(68,729)	0	(68,729)
Effect of foreign currency exchange	1,136	0	1,136
Balance due to related parties, October 31, 2014	$      181,280	$       152,352	$      333,632

Schedule of Segment Reporting Information, by Segment

	Three Months Ended October 31,		Six Months Ended October 31,
	2014	2013	2014	2013
Revenues:
Chinese medicine – third party	$         576,868	$         577,262	$      1,099,061	$      1,148,822
Chinese medicine – related party	0	0	0	0
Total Chinese medicine	576,868	577,262	1,099,061	1,148,822
Stevioside – third party	2,396,023	1,656,015	4,824,731	2,658,050
Stevioside – related party	1,054,439	590,680	1,940,047	1,733,991
Total Stevioside	3,450,462	2,246,695	6,764,778	4,392,041
Total segment and consolidated revenues	$      4,027,330	$      2,823,957	$      7,863,839	$      5,540,863
Interest (expense) income:
Chinese medicine	$                 (14)	$                134	$                   126	$                278
Stevioside	(64,352)	(17,996)	(127,446)	(33,528)
Total segment and consolidated interest expense	$         (64,366)	$         (17,862)	$         (127,320)	$         (33,250)
Depreciation and amortization:
Chinese medicine	$            20,383	$           23,557	$               39,372	$           46,033
Stevioside	446,138	519,051	1,133,561	1,042,240
Total segment and consolidated depreciation and amortization	$         466,521	$         542,608	$         1,172,933	$     1,088,273
Income (loss) before income taxes:
Chinese medicine	$           33,361	$        (42,142)	$              57,477	$         (51,000)
Stevioside	(247,850)	(843,764)	(679,457)	(1,467,270)
Corporate and other	(17,030)	(71,930)	(86,211)	(24,940)
Total consolidated (loss) income before income taxes	$       (231,519)	$      (957,836)	$          (708,191)	$   (1,543,210)

Schedule of Segment Asset

	October 31, 2014	April 30, 2014
Segment tangible assets:
Chinese medicine	$       647,545	$       605,918
Stevioside	13,938,733	14,332,440
Corporate and other	0	0
Total consolidated assets	$ 14,586,278	$ 14,938,358

Customer concentrations table

	Net Sales
	For the six months ended October 31, 2014		For the six months ended October 31, 2013
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Qufu Shengwang Import and Export Trade Co., Ltd*	-	31.6%	-	44.2%
Qingdao Runde Biological Technology Co.Ltd	-	13.0%	-	13.6%
Zhonghua (Qingdao) Industrial Co., Ltd.	-	20.7%	-	-
Guangdong Tengjun Veterinary Medicine Co., Ltd	-	-	12.5%	-
Total	-	65.3%	12.5%	57.8%

Vendor concentrations table

	Net Purchases
	For the six months ended October 31, 2014		For the six months ended October 31, 2013
	Chinese Medicine	Stevioside	Chinese Medicine	Stevioside
Shandong Heze Zhongshun Pharmaceutical Co., Ltd	-	-	19.6%	-
Bozhou Weitao Pharmaceutical Co., Ltd	-	-	13.8%	-
Qufu Longheng Materials Co., Ltd	-	-	21.3%	-
Gansu Fanzhi Biology Techonology Co.,Ltd	9.4%	-	15.9%	-
Gansu DunHuang Agriculture Products Co.,Ltd	-	-	-	10.9%
Gansu Puhua Stevia Develop Co., Ltd	-	25.4%	-	-
Shandong Jinhuaxia Environment Engineering Co. Ltd.	-	-	-	12.2%
Mingguang Xingshi Stevia Corp.	-	15.8%	-	-
Ganzhou Julong High Tech Co., Ltd	-	15.9%	-	-
Total	9.4%	57.1%	70.6%	23.1%